New hope for kids with rare gut disease: dupilumab trial launches
NCT ID NCT07257835
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing the drug dupilumab in 20 children whose eosinophilic gastrointestinal disorders have not responded to other treatments. The goal is to see if dupilumab can heal ulcers and reduce inflammation in the stomach and gut. Children receive injections every one or two weeks, depending on their weight.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dupilumab
What this could lead to
If it works, this could offer a new treatment option for children with severe, hard-to-treat eosinophilic gastrointestinal disorders.
What could go wrong
This is a small, early observational study with only 20 children, so results may not apply to everyone. Dupilumab can cause injection site reactions and allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GASTROINTESTINAL DISORDERS (EGIDS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
201102
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••